Literature DB >> 11122866

Modern management of the cancer anorexia-cachexia syndrome.

K A Nelson1.   

Abstract

The cancer anorexia-cachexia syndrome is common, occurring in 80% of patients with advanced-stage cancer, and it is one of the most frequent causes of death in patients with cancer. It is a complex problem involving abnormalities in protein, carbohydrate, and fat metabolism. Tumors have both direct and indirect effects that result in anorexia and weight loss. The disease burden does not necessarily correlate with the degree of cachexia. In addition to the physical manifestations, the resulting abnormalities have a significant psychologic effect on patients and their families. Although there is no treatment to reverse the process, pharmacologic and nonpharmacologic measures can enhance food intake and improve quality of life.

Entities:  

Mesh:

Year:  2000        PMID: 11122866     DOI: 10.1007/s11912-000-0031-y

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  31 in total

1.  Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial.

Authors:  F De Conno; C Martini; E Zecca; A Balzarini; P Venturino; L Groff; A Caraceni
Journal:  Eur J Cancer       Date:  1998-10       Impact factor: 9.162

Review 2.  Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature.

Authors:  M Mann; E Koller; A Murgo; S Malozowski; J Bacsanyi; M Leinung
Journal:  Arch Intern Med       Date:  1997 Aug 11-25

3.  Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.

Authors:  C L Loprinzi; J W Kugler; J A Sloan; J A Mailliard; J E Krook; M B Wilwerding; K M Rowland; J K Camoriano; P J Novotny; B J Christensen
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

4.  A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer.

Authors:  E Bruera; K Macmillan; N Kuehn; J Hanson; R N MacDonald
Journal:  Cancer       Date:  1990-09-15       Impact factor: 6.860

5.  Assessment of upper gastrointestinal motility in the cancer-associated dyspepsia syndrome.

Authors:  K A Nelson; T D Walsh; F G Sheehan; P B O'Donovan; G W Falk
Journal:  J Palliat Care       Date:  1993       Impact factor: 2.250

6.  Corticosteroid toxicity in neuro-oncology patients.

Authors:  D E Weissman; D Dufer; V Vogel; M D Abeloff
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

7.  Metoclopramide in anorexia caused by cancer-associated dyspepsia syndrome (CADS).

Authors:  K A Nelson; T D Walsh
Journal:  J Palliat Care       Date:  1993       Impact factor: 2.250

8.  Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS.

Authors:  J E Beal; R Olson; L Laubenstein; J O Morales; P Bellman; B Yangco; L Lefkowitz; T F Plasse; K V Shepard
Journal:  J Pain Symptom Manage       Date:  1995-02       Impact factor: 3.612

9.  The symptoms of advanced cancer.

Authors:  S Donnelly; D Walsh
Journal:  Semin Oncol       Date:  1995-04       Impact factor: 4.929

10.  A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss.

Authors:  D C McMillan; S J Wigmore; K C Fearon; P O'Gorman; C E Wright; C S McArdle
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more
  2 in total

1.  Cachexia worsens prognosis in patients with resectable pancreatic cancer.

Authors:  Jeannine Bachmann; Mathias Heiligensetzer; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni
Journal:  J Gastrointest Surg       Date:  2008-03-18       Impact factor: 3.452

2.  Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function.

Authors:  Jeannine Bachmann; Knut Ketterer; Christiane Marsch; Kerstin Fechtner; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni
Journal:  BMC Cancer       Date:  2009-07-28       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.